Madrigal Pharmaceuticals, Inc.
HealthcareNASDAQ:MDGL · NASDAQ Global Select
+$6.49 today
Vol 0.20M · Avg 0.31M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.8%
avg -62.7%
ROIC
-31.6%
avg -103.0%
ROA
-22.9%
avg -43.8%
Analysis
ROA is currently the strongest return metric at -22.9% versus its period average of -43.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
William J. Sibold | Chief Executive Officer, President & Director | $2.37M | — | 60 | $161,829.00 | 0.70% |
Rebecca A. Taub | Founder, Senior Scientific & Medical Advisor and Director | $1.22M | — | 74 | $452,213.00 | 1.96% |
Mardi C. Dier | Executive Vice President & Chief Financial Officer | $1.21M | — | 62 | $12,610.00 | 0.05% |
Carole Huntsman | Executive Vice President & Chief Commercial Officer | $1.08M | — | 61 | $12,692.00 | 0.06% |
David Soergel | Executive VP & Chief Medical Officer | $1.08M | — | 58 | $10,033.00 | 0.04% |
Shannon Kelley | Executive Vice President, Chief Legal Officer & Corporate Secretary | $1.07M | — | 51 | $12,138.00 | 0.05% |
Clint Wallace | Executive Vice President & Chief Human Resources Officer | — | — | — | — | — |
Mark Underwood | Executive Vice President of Business Planning & Operations | — | — | — | — | — |
Ronald Filippo | Executive Vice President & Chief Information Officer | — | — | — | — | — |
Rita Thakkar | Senior VP & Chief Accounting Officer | — | — | 52 | $1,826.00 | <0.01% |
Tina E. Ventura | Chief Investor Relations Officer | — | — | — | $17,841.00 | 0.08% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
160
$68.75M
Net Sentiment
$68.75M
Net selling
Most Active
Taub Rebecca
42 transactions
1–10 of 160
Analysis
Insiders reported 0 buys worth $0.00 and 160 sells worth $68.75M over the last 12 months. That adds up to net selling of $68.75M. Taub Rebecca was the most active insider with 42 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Moderna, Inc.
NASDAQ:MRNA
$19.80B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.48B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.81B
Baxter International Inc.
NYSE:BAX
$10.77B
Bio-Techne Corporation
NASDAQ:TECH
$8.45B
Abivax S.A.
NASDAQ:ABVX
$6.33B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.06B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.08B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Who manages MDGL?
Madrigal Pharmaceuticals, Inc. (MDGL) lists 11 active executives. The top listed executive is David Soergel, Executive VP & Chief Medical Officer.
Are MDGL insiders buying or selling?
Recent insider activity shows net selling of $47.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.